Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 2
2016 1
2017 3
2018 2
2019 3
2020 4
2021 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers.
Tagliamento M, Morfouace M, Loizides C, Oliveira J, Greillier L, Raimbourg J, Toffart AC, Chatellier T, Cloarec N, Sullivan I, Brasiuniene B, Duruisseaux M, Oselin K, Robert MS, Fernandes C, Poncin A, Blay JY, Besse B, Girard N. Tagliamento M, et al. Among authors: morfouace m. NPJ Precis Oncol. 2024 Feb 16;8(1):37. doi: 10.1038/s41698-024-00518-9. NPJ Precis Oncol. 2024. PMID: 38366021 Free PMC article.
Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study.
Morfouace M, Horak P, Kreutzfeldt S, Stevovic A, de Rojas T, Denisova E, Hutter B, Bautista F, Oliveira J, Defachelles AS, White J, Kasper B, Preusser M, Golfinopoulos V, Pfister S, Van der Graaf W, Wardelmann E, Shenjere P, Fröhling S, McCabe MG. Morfouace M, et al. Eur J Cancer. 2023 Jan;178:216-226. doi: 10.1016/j.ejca.2022.10.020. Epub 2022 Nov 5. Eur J Cancer. 2023. PMID: 36470093 Free article.
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial.
Galot R, Le Tourneau C, Saada-Bouzid E, Daste A, Even C, Debruyne P, Henry S, Zanetta S, Rutten A, Licitra L, Canon JL, Kaminsky MC, Specenier P, Rottey S, Guigay J, Kong A, Tinhofer I, Borcoman E, Dirix L, Raveloarivahy T, Fortpied C, Vanlancker M, Morfouace M, Govaerts AS, Machiels JP. Galot R, et al. Among authors: morfouace m. Eur J Cancer. 2021 Oct 9;158:17-26. doi: 10.1016/j.ejca.2021.09.003. Online ahead of print. Eur J Cancer. 2021. PMID: 34638090
Molecular Characterization of Ovarian Yolk Sac Tumor (OYST).
Hodroj K, Stevovic A, Attignon V, Ferraioli D, Meeus P, Croce S, Chopin N, Rossi L, Floquet A, Rousset-Jablonski C, Tredan O, Guyon F, Treilleux I, Rannou C, Morfouace M, Ray-Coquard I. Hodroj K, et al. Among authors: morfouace m. Cancers (Basel). 2021 Jan 9;13(2):220. doi: 10.3390/cancers13020220. Cancers (Basel). 2021. PMID: 33435376 Free PMC article.
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
Slavish PJ, Chi L, Yun MK, Tsurkan L, Martinez NE, Jonchere B, Chai SC, Connelly M, Waddell MB, Das S, Neale G, Li Z, Shadrick WR, Olsen RR, Freeman KW, Low JA, Price JE, Young BM, Bharatham N, Boyd VA, Yang J, Lee RE, Morfouace M, Roussel MF, Chen T, Savic D, Guy RK, White SW, Shelat AA, Potter PM. Slavish PJ, et al. Among authors: morfouace m. Cancer Res. 2020 Sep 1;80(17):3507-3518. doi: 10.1158/0008-5472.CAN-19-3934. Epub 2020 Jul 10. Cancer Res. 2020. PMID: 32651255 Free PMC article.
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.
Hoogstrate Y, Vallentgoed W, Kros JM, de Heer I, de Wit M, Eoli M, Sepulveda JM, Walenkamp AME, Frenel JS, Franceschi E, Clement PM, Weller M, van Royen ME, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, Golfinopoulos V, van den Bent M, French PJ. Hoogstrate Y, et al. Among authors: morfouace m. Neurooncol Adv. 2019 Dec 9;2(1):vdz051. doi: 10.1093/noajnl/vdz051. eCollection 2020 Jan-Dec. Neurooncol Adv. 2019. PMID: 32642719 Free PMC article.
Defining EGFR amplification status for clinical trial inclusion.
French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M. French PJ, et al. Among authors: morfouace m. Neuro Oncol. 2019 Oct 9;21(10):1263-1272. doi: 10.1093/neuonc/noz096. Neuro Oncol. 2019. PMID: 31125418 Free PMC article.
CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.
Teitz T, Fang J, Goktug AN, Bonga JD, Diao S, Hazlitt RA, Iconaru L, Morfouace M, Currier D, Zhou Y, Umans RA, Taylor MR, Cheng C, Min J, Freeman B, Peng J, Roussel MF, Kriwacki R, Guy RK, Chen T, Zuo J. Teitz T, et al. Among authors: morfouace m. J Exp Med. 2018 Apr 2;215(4):1187-1203. doi: 10.1084/jem.20172246. Epub 2018 Mar 7. J Exp Med. 2018. PMID: 29514916 Free PMC article.
17 results